Barron's Bounce: Sarepta's Soaring Fortunes

The biotech stock's shares surged after Barron's said the market is underestimating potential sales of its Duchenne Muscular Dystrophy treatment. Ben Levisohn and Jack Hough discuss. Plus, a positive take on U.S. banks, including Bank of America.